Evelo Biosciences (NASDAQ:EVLO – Get Free Report) is expected to be announcing its resultson Monday, August 31st. Analysts expect Evelo Biosciences to announce earnings of ($10.1333) per share for the quarter.
Evelo Biosciences Stock Performance
Shares of NASDAQ EVLO opened at $0.00 on Friday. The company has a market cap of $1,884.00, a price-to-earnings ratio of -0.00 and a beta of 1.62. Evelo Biosciences has a twelve month low of $0.00 and a twelve month high of $0.00.
Evelo Biosciences Company Profile
Evelo Biosciences is a clinical-stage biotechnology company developing orally delivered immunomodulatory therapies that leverage the gut-body network. The company’s proprietary platform is designed to mimic signals normally generated by gut commensal bacteria to regulate immune function throughout the body. Evelo’s approach focuses on non-live, inactivated microbial derivatives, aiming to offer a new class of biologics that can be administered by mouth and engage mucosal immune pathways to treat a range of diseases.
The company’s pipeline spans inflammatory, autoimmune and oncology indications.
Read More
- Five stocks we like better than Evelo Biosciences
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Receive News & Ratings for Evelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
